Purple Biotech Regains Compliance with Nasdaq

Core Viewpoint - Purple Biotech Ltd. has regained compliance with Nasdaq's minimum bid price requirement, allowing for continued listing on the Nasdaq Capital Market [2]. Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing a next-generation immunotherapy platform aimed at maximizing anti-cancer potency while minimizing toxicity [3]. - The company is advancing its lead program, CAPTN-3, which utilizes masked tri-specific antibodies to target tumors and engage T cells and NK cells [3]. - The lead candidate, IM1240, is progressing towards clinical trials, while the second candidate, IM1305, is in preclinical development [3]. - The pipeline includes additional clinical-stage assets such as CM24, a CEACAM1-blocking antibody, and NT219, a dual IRS1/2 and STAT3 inhibitor, both of which are in Phase 2 studies for various cancers [3].